Mizuho Securities Thinks Revance Therapeutics’ Stock is Going to Recover


Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC) yesterday and set a price target of $37. The company’s shares closed yesterday at $13.59, close to its 52-week low of $12.87.

Yang said:

“We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 11.8% and a 42.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.

Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $36.80.

See today’s analyst top recommended stocks >>

Based on Revance Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $40.62 million. In comparison, last year the company had a GAAP net loss of $35.04 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts